Clinical Trials Browser

Phase 2 × Neoplasms × danvatirsen × Clear all

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

84 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms